These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 29872177)

  • 1. Safety of combining radiotherapy with immune-checkpoint inhibition.
    Hwang WL; Pike LRG; Royce TJ; Mahal BA; Loeffler JS
    Nat Rev Clin Oncol; 2018 Aug; 15(8):477-494. PubMed ID: 29872177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogressive disease: recognizing a novel pattern to improve patient management.
    Champiat S; Ferrara R; Massard C; Besse B; Marabelle A; Soria JC; Ferté C
    Nat Rev Clin Oncol; 2018 Dec; 15(12):748-762. PubMed ID: 30361681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for checkpoint inhibition in hematologic malignancies.
    Atanackovic D; Luetkens T
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
    Azoury SC; Straughan DM; Shukla V
    Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Toxicity.
    Mantia CM; Buchbinder EI
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):275-290. PubMed ID: 30833000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
    King GT; Sharma P; Davis SL; Jimeno A
    Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.